» Articles » PMID: 20331929

Treatment of Cannabis Use Among People with Psychotic or Depressive Disorders: a Systematic Review

Overview
Specialty Psychiatry
Date 2010 Mar 25
PMID 20331929
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This article systematically reviews the evidence from randomized controlled trials (RCTs) for pharmacologic and psychological approaches to the treatment of cannabis use among individuals with psychotic or depressive disorders.

Data Sources: A systematic literature search was conducted using the PubMed and PsychINFO databases from inception to December 2008. Individual searches in cannabis use (search terms: marijuana, cannabis, marijuana abuse, cannabis abuse, marijuana usage, cannabis usage), mental disorders (search terms: mood disorders, affective disorders, anxiety disorders, anxiety, depressive disorder, depression, psychotic disorders, psychosis, mental disorders), and pharmacotherapy (search terms: medication, drug therapy, pharmacotherapy, psychopharmacology, clinical trials, drug trial, treatment trial) were conducted and limited to humans, adolescents and adults.

Study Selection: A search combining the individual cannabis use, mental disorder and pharmacotherapy searches produced 1,713 articles (PubMed = 1,398; PsychINFO = 315). Combining the cannabis use and mental disorder searches while limiting them to English articles and RCTs produced a total of 286 articles (PubMed = 228; PsychINFO = 58). From this literature, there were 7 RCTs conducted among mental health clients that reported cannabis use outcomes using pharmacologic or psychological interventions.

Data Synthesis: While few RCTs have been conducted, there is evidence that pharmacologic and psychological interventions are effective for reducing cannabis use in the short-term among people with psychotic disorders or depression.

Conclusions: Although it is difficult to make evidence-based treatment recommendations due to the paucity of research in this area, available studies indicate that effectively treating the mental health disorder with standard pharmacotherapy may be associated with a reduction in cannabis use and that longer or more intensive psychological interventions rather than brief interventions may be required, particularly among heavier users of cannabis and those with more chronic mental disorders. Specific recommendations regarding the type and length of specific psychological treatments cannot be made at this time, although motivational interviewing and cognitive-behavioral therapy approaches appear most promising.

Citing Articles

Avatar Intervention in Virtual Reality for Cannabis Use Disorder in Individuals With Severe Mental Disorders: Results From a 1-Year, Single-Arm Clinical Trial.

Giguere S, Beaudoin M, Dellazizzo L, Phraxayavong K, Potvin S, Dumais A JMIR Ment Health. 2024; 11:e58499.

PMID: 39602812 PMC: 11612600. DOI: 10.2196/58499.


How to quit cannabis when you have a mental illness: study from the perspective of patients who have successfully quit.

Bruins J, Crutzen S, Veling W, Castelein S BJPsych Bull. 2023; :1-7.

PMID: 37694506 PMC: 11543310. DOI: 10.1192/bjb.2023.69.


Anxiety sensitivity and cigarette use on cannabis use problems, perceived barriers for cannabis cessation, and self-efficacy for quitting among adults with cannabis use disorder.

Orr M, Heggeness L, Mehta N, Moya J, Manning K, Garey L Addict Behav. 2022; 137:107509.

PMID: 36194977 PMC: 10080994. DOI: 10.1016/j.addbeh.2022.107509.


The implementation and sustainment facilitation strategy improved implementation effectiveness and intervention effectiveness: Results from a cluster-randomized, type 2 hybrid trial.

Garner B, Gotham H, Chaple M, Martino S, Ford Ii J, Roosa M Implement Res Pract. 2022; 1.

PMID: 36189179 PMC: 9523796. DOI: 10.1177/2633489520948073.


Insights About Cannabis and Psychosis Using Video Games for Young People With a First Episode of Psychosis, Particularly Those From Black Racialized Communities: Protocol for a Mixed Methods Study.

Archie S, Palaniyappan L, Olagunju A, Johnson N, Kozloff N, Sadeh E JMIR Res Protoc. 2022; 11(5):e36758.

PMID: 35389874 PMC: 9166641. DOI: 10.2196/36758.